Biographies

E-mail this page

(All fields required)

Recipient's email address

Please enter a valid email.

Your name

Please enter your name.

Your email address

Please enter a valid email.

Find another Doctor or Researcher

High Res

James I. Geller, MD

Medical Director, Kidney and Liver Tumors Program

Co-Medical Director, Retinoblastoma Program

Associate Director, Global Cancer Programs

Associate Professor, UC Department of Pediatrics

Phone: 513-636-4266

Fax: 513-636-3549

Email: james.geller@cchmc.org

Show All

Specialties

Clinical Interests

Developmental therapeutics; renal / liver / retinoblastoma / neuro-oncology

Research Interests

Elucidating ways to translate the use of biological response modifiers in combination with conventional chemotherapeutics

Biography

James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with the University of Cincinnati and Children's Hospital Medical Center in the capacity of associate professor of pediatrics.

Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare/Retinoblastoma Committee as both a Steering/Voting Member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as Steering/Voting Member, RTC Sub-Committee Chair of Developmental Therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.

Education and Training

MD: Sackler School of Medicine, 1997.

Residency: New York Medical College, 2000.

Fellowship: St Jude Children's Research Hospital, 2004.

Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.

Publications

View PubMed Publications

Geller JI, Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011 Sep;41(9):1183-97.

Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010 Jul 1;54(7):1035-7.

Cripe TP. Adenovirus gene therapy for pediatric cancers: shall we gather at the liver? Pediatr Blood Cancer. 2009 Aug;53(2):133-5.

Geller JI, Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatr Blood Cancer. 2009 Mar;52(3):430.

Geller JI, Leslie ND, Yin H. Malignant Rhabdoid Tumor. eMedicine from WebMD. 2009 Dec. Available online.

Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.

Geller JI. Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time? Cancer. 2008 Sep 1;113(5):893-6.

Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008 Apr 1;112(7):1607-16.

Geller JI, Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatr Blood Cancer. 2006 Apr;46(4):527.

Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004 Oct 1;101(7):1575-83.

Grants

Identification, selection, and validation of rationale molecular targets that result from this High-Risk Wilms ‘TARGET’ initiative. National Institutes of Health. 2009 - 2011.